1. Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review
- Author
-
Mercè Brunet, José M. Miró, Natalia A Diaz, Montserrat Tuset, Marta Crespo, Mónica Marín-Casino, Pablo Ruiz, Juan Ambrosioni, Dolores Redondo-Pachón, Frederic Cofan, Gonzalo Crespo, and Asunción Moreno
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,030106 microbiology ,Human immunodeficiency virus (HIV) ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,Internal medicine ,medicine ,Case Series ,030212 general & internal medicine ,Transplantation ,Everolimus ,business.industry ,Cobicistat ,HIV ,SOT ,Tacrolimus ,Regimen ,Infectious Diseases ,Sirolimus ,business ,ART ,Transplant recipient ,medicine.drug - Abstract
People living with HIV should be considered candidates for solid-organ transplantation (SOT). However, managing HIV-infected patients undergoing SOT represents a major challenge due to the potential drug-drug interactions between antiretroviral drugs and immunosuppressive agents, particularly when resorting to antiretroviral drugs that require pharmacokinetic enhancers. We report three cases of cobicistat-tacrolimus co-administration, two of which also include the co-administration of mTOR inhibitors, in HIV-positive patients undergoing SOT (2 kidney and 1 liver recipient). We review previously reported cases and provide recommendations for initial management following transplantation.
- Published
- 2021